Data will be presented during “TCT 2011” spotlight session

“One in three severe heart attack patients has suboptimal microcirculatory blood flow even after coronary angioplasty, increasing their risk of death within a year by almost three-fold. PICSO® is designed to help these at-risk patients.”
-Jon H. Hoem, CEO, Miracor Medical Systems

VIENNA, Austria, Miracor Medical Systems GmbH announced today that data will be reported during next week’s “TCT (Transcatheter Cardiovascular Therapeutics) 2011” scientific meeting in San Francisco. The data show that the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) system is safe and feasible during elective percutaneous coronary intervention (PCI) using a femoral vein approach. (Click here for 5 minute “Corporate Preview” video with PICSO® animation.) 

The PICSO® procedure was performed successfully on 10 patients by Prof. Dr. med. Jan Piek and his group at the Academic Medical Center, Amsterdam, The Netherlands, as part of the ‘Prepare PISCO®’ study of stable angina patients. Based on these outstanding clinical results, Miracor will soon initiate the ‘Prepare RAMSES’ study in acute coronary syndrome patients.

“In spite of a successful primary PCI, suboptimal myocardial reperfusion occurs in approximately 30 percent of STEMI patients, and this occurrence is strongly correlated with unfavorable outcomes for patients,” said Prof. Piek. “Our study demonstrates that PICSO significantly increased the redistribution of blood into the ischemic myocardium, which is very encouraging as we look to enroll patients into the multi-centre ‘Prepare RAMSES’ study,” added Prof. Piek.

Prof. Piek’s results will be presented during a special spotlight session on ‘Approaches to Reperfusion Injury and Enhancing Myocardial Recovery’ moderated by Dr. Mitchell W. Krucoff (Duke University Medical Centre, Durham, NC) and Dr. Holger Thiele (University of Leipzig Medical Center, Germany).

“We are extremely pleased to have successfully completed the ‘Prepare PICSO®’ study and now look forward with great enthusiasm to the ‘Prepare RAMSES’ study ,” said Jon H. Hoem, Miracor CEO. “The ‘Prepare RAMSES’ study will help us understand the logistics of the technology in an acute setting and also how the technology effects important endpoints such as infarct size, ST-segment ECG changes, enzyme release and left ventricular function.”

Source: Miracor Medical Systems GmbH